Abstract Library

#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Plastino F, Iacovazzo D, Schinzari G, Barile R, Lugli F,

Keywords: everolimus, prrt,

#764 The Experience of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms

Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a Neuroendocrine Tumor Board established at our University Hospital.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Bianchi A, Iacovazzo D, Plastino F, Lugli F, Pontecorvi A,

Keywords: tumor board, database, guidelines,

#542 Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms

Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bianchi A, Iacovazzo D, Plastino F, Lugli F, Pontecorvi A,

Keywords: tumor board, neuroendocrine, database, guidelines,